|
Market Closed -
London S.E.
12:35:21 2026-10-30 EDT
|
5-day change | 1st Jan Change | ||
| 1,855.00 GBX | +2.26% |
|
-2.06% | +1.67% |
| 10-30 | GSK plc : DZ Bank remains Neutral | ZD |
| 10-30 | AlphaValue/Baader Europe Upgrades GSK to Buy Rating | MT |
Company Valuation: GSK plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 80,458 | 58,381 | 59,112 | 54,944 | 73,201 | 74,367 | - | - |
| Change | - | -27.44% | 1.25% | -7.05% | 33.23% | 1.59% | - | - |
| Enterprise Value (EV) 1 | 100,296 | 75,578 | 74,152 | 68,039 | 87,654 | 96,271 | 93,451 | 90,715 |
| Change | - | -24.65% | -1.89% | -8.24% | 28.83% | 9.83% | -2.93% | -2.93% |
| P/E | 18.6x | 3.93x | 11.9x | 21.3x | 12.9x | 14.8x | 12x | 11.1x |
| PBR | 5.34x | 5.47x | 4.4x | 4.02x | 4.51x | 4.17x | 4.13x | 3.55x |
| PEG | - | 0x | -0.2x | -0.4x | 0x | -1.3x | 0.5x | 1.39x |
| Capitalization / Revenue | 2.36x | 1.99x | 1.95x | 1.75x | 2.24x | 2.2x | 2.1x | 2.04x |
| EV / Revenue | 2.94x | 2.58x | 2.45x | 2.17x | 2.68x | 2.84x | 2.64x | 2.49x |
| EV / EBITDA | 8.85x | 7.23x | 6.37x | 6.36x | 7.77x | 8.41x | 7.61x | 7.19x |
| EV / EBIT | 11.4x | 9.27x | 8.44x | 7.44x | 8.96x | 9.3x | 8.46x | 7.9x |
| EV / FCF | 22.6x | 12.1x | 13.6x | 13x | 13.7x | 19.9x | 19.4x | 14.9x |
| FCF Yield | 4.42% | 8.28% | 7.36% | 7.67% | 7.32% | 5.02% | 5.15% | 6.7% |
| Dividend per Share 2 | 1 | 0.6125 | 0.58 | 0.61 | 0.66 | 0.6958 | 0.748 | 0.7824 |
| Rate of return | 4.98% | 4.26% | 4% | 4.53% | 3.62% | 3.75% | 4.03% | 4.22% |
| EPS 2 | 1.082 | 3.662 | 1.216 | 0.632 | 1.411 | 1.253 | 1.54 | 1.664 |
| Distribution rate | 92.4% | 16.7% | 47.7% | 96.5% | 46.8% | 55.5% | 48.6% | 47% |
| Net sales 1 | 34,114 | 29,324 | 30,328 | 31,376 | 32,667 | 33,844 | 35,365 | 36,493 |
| EBITDA 1 | 11,330 | 10,449 | 11,635 | 10,693 | 11,278 | 11,442 | 12,285 | 12,617 |
| EBIT 1 | 8,806 | 8,151 | 8,786 | 9,148 | 9,783 | 10,346 | 11,047 | 11,487 |
| Net income 1 | 4,385 | 14,956 | 4,928 | 2,575 | 5,716 | 5,012 | 6,090 | 6,607 |
| Net Debt 1 | 19,838 | 17,197 | 15,040 | 13,095 | 14,453 | 21,904 | 19,084 | 16,349 |
| Reference price 2 | 20.08 | 14.38 | 14.50 | 13.46 | 18.24 | 18.55 | 18.55 | 18.55 |
| Nbr of stocks (in thousands) | 4,006,383 | 4,060,999 | 4,076,145 | 4,080,519 | 4,012,126 | 4,009,000 | - | - |
| Announcement Date | 2/9/22 | 2/1/23 | 1/31/24 | 2/5/25 | 2/4/26 | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 14.63x | 2.84x | 8.41x | 3.75% | 99.63B | |
| 41.42x | 14.04x | 31.11x | 0.48% | 1,263B | |
| 39.99x | 6.71x | 18.89x | 1.95% | 658B | |
| 36.71x | 8.6x | 17.71x | 2.33% | 521B | |
| 21.74x | 5.27x | 13.12x | 2.48% | 391B | |
| 106.24x | 6.06x | 25.8x | 2.28% | 369B | |
| 23.19x | 5.95x | 14.36x | 2.69% | 307B | |
| 24.47x | 4.89x | 13.59x | 1.77% | 290B | |
| 29.55x | 7.53x | 13.48x | 2.16% | 252B | |
| -41.18x | 7.46x | 46.76x | 1.93% | 212B | |
| Average | 29.68x | 6.94x | 20.32x | 2.18% | 436.16B | |
| Weighted average by Cap. | 36.64x | 8.69x | 22.48x | 1.74% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GSK Stock
- Valuation GSK plc
Select your edition
All financial news and data tailored to specific country editions
